# A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

> **NCT04030026** · PHASE2 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04030026
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-29
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-05-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030026, "A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04030026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*